DRUG · Unmapped registry intervention
Levomilnacipran ER
Find medicine records ·
Find other trials using this name
Clinical trial
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
NCT01085812
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRelapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
PlaceboDRUG
Sponsors & collaborators
Forest Laboratorieslead sponsor
Mapped research locations
ChicagoIllinois, United States2BostonMassachusetts, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1San AntonioTexas, United States1SeattleWashington, United States1San DiegoCalifornia, United States1PortlandOregon, United States1OrlandoFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01085812 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.